

Please type a plus sign (+) inside this box →

十

Substitute for form 1449A/B/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1 HHS Reference No. F-088-2005/0-IIS-03

Substitute for form 1449A/B/PTO		<b>Complete if Known</b>
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Application Number
(Use as many sheets as necessary)		10/579,007
		Filing Date
		October 19, 2006
		First Named Inventor
		Dennis L. Panicali
		Group Art Unit
		1633
		Examiner Name
		Anne Marie Sabrina Wehbe
		Attorney Docket Number
		701278
		HHS Reference No.
		E-088-2005/0-US-03
Sheet	1	of
	1	

U.S. PATENT DOCUMENTS

## FOREIGN PATENT DOCUMENTS

---

**OTHER - NON PATENT LITERATURE DOCUMENTS**

OTHER - NON-PATENT LITERATURE DOCUMENTS			
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation *
	A Z	APOSTOLOPOULOS et al., "Cellular Mucins: Targets for Immunotherapy," <i>Critical Reviews in Immunology</i> , 14: 293-309 (1994)	
	B A	KAUFMAN, et al., "Immunotherapy for pancreatic cancer: current concepts," <i>Hematol. Oncol. Clin. N. Amer.</i> , 16: 159-197 (2002)	
	B B	MARSHALL, John, "Carcinoembryonic Antigen-Based Vaccines," <i>Seminars in Oncology</i> , 30(3): 30-36 (2003)	
	B C	REYNOLDS, et al., "HLA-Independent Heterogeneity of CD8+ T Cell Responses to MAGE-3, Melan-A/MART-1, gp100, Tyrosinase, MC1R, and TRP-2 in Vaccine-Treated Melanoma Patients," <i>Journal of Immunology</i> , 161: 6970-6976 (1998)	
	B D	WELLINGTON, et al., "Measles, Mumps, Rubella Vaccine (Priorix™, GSK-MMR) A Review of Its Use in the Prevention of Measles, Mumps and Rubella," <i>Drugs</i> , 63 (19): 2107-2126 (2003)	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /AW/ (07/07/2011)

**Examiner Signature** /Anne Marie Webbel (07/07/2011)      **Date Considered** 07/07/2011

- If the reference is not in English, then at least one of the following is provided: (a) an English translation in whole or in part or (b) a concise statement of relevance in the form of, for example, an English language counterpart, an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office.